Psoriasis in Malaysia: Support Resources

Problem of Psoriasis in Malaysia

Psoriasis is common and affects 3% of Malaysians i.e. @ 400,000. It is usually non-life-threatening, but is a distressing condition as it can affect any part of the skin, scalp and nails. Fortunately, life-threatening and widespread disease which can affect one's job is not common, and the majority is able to perform normally in their respective occupations albeit with some social restrictions. There are in fact many prominent and successful persons with psoriasis in the Malaysian scene in business, politics and various professions who have psoriasis and have learnt to live with and overcome the disease.

Reference: http://www.dermatology.org.my/overview_psoriasis.html

Psoriasis Association of Malaysia

The Psoriasis Association of Malaysia is a registered, non-profit, self-help, lay organization of psoriasis sufferers started in 1987 to help improve the life of people with psoriasis and their families. It is funded by public donations, membership dues and grants from friends in the pharmaceutical industry and is served by a Medical Advisor who is a dermatologist from the Dermatological Society of Malaysia.

Its main goals are:
1. To increase public awareness and acceptance of psoriasis.
2. To provide continuing education and information to persons with psoriasis.
3. To provide a support group for persons with psoriasis and their families.

For more information, please visit the following links:

Contact for Psoriasis Association of Malaysia
Address: 
No 1, Jala 14/2C, Taman Serdang Utama,
43300 Seri Kembangan Selangor
Tel: 03-80484335
Fax: 03- 89481537

Links for Psoriasis Malaysia:

  1. Skin specialists in Kuala Lumpur
  2. http://www.webmd.com/skin-problems-and-treatments/psoriasis-treatment-11/overvie 
  3. https://www.psoriasis.org/

Location: Malaysia

Comments

Post a Comment

Popular posts from this blog

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive re...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
2026 Evidence & Treatment Guide GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly . The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals. Updated: September 27, 2026   |   Regulatory reference: U.S. FDA labeling   |   Scope: Adult obesity treatment unless otherwise stated Important medical note: This page is educational information, not a diagnosis or personal treatm...
Read more

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2, 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that ad...
Read more

Telehealth Peptide Providers 2026: How to Compare Prescription GLP-1s, Other Peptides, Compounding, Clinical Oversight and Pharmacy Sources

Image
A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...
Read more

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: September 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection in...
Read more

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

Image
By Dr. Frank Yap, MD  |  Originally published April 2026  |  Fully updated August 26, 2026 for the FDA's July 2026 compounding committee vote Quick Answer As of August 2026, GLP-1 receptor agonists (semaglutide, tirzepatide) remain the only peptides in this guide with full FDA approval. On July 23–24, 2026, an FDA advisory committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list of substances compounding pharmacies may use — but that vote is non-binding, and none of the six is lawful to compound yet; formal rulemaking is expected to take 12–24 months. Separately, AOD-9604 failed its pivotal human obesity trial back in 2007. The best human evidence among the non-GLP-1 peptides here belongs to topical GHK-Cu (skin) and Selank (anxiety); the weakest belongs to BPC-157 and TB-500 (mostly animal data). Any protocol should run through a licensed physician — not a gray-market vendor. Medical & regu...
Read more

Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss: What the Evidence Shows

Image
Updated September 25, 2026 Popular GLP-1-based medicines are now at the center of a growing legal and medical debate over a rare form of sudden vision loss called nonarteritic anterior ischemic optic neuropathy (NAION) . Patients in the United States have filed lawsuits against the manufacturers of widely used medicines including Ozempic, Wegovy, Mounjaro and Zepbound , alleging that the drugs caused NAION and that patients were not adequately warned about the potential risk. Those lawsuits are allegations at the moment—not findings that the medications caused the injuries. The scientific evidence is still evolving and is not completely consistent. Importantly, the regulatory evidence is stronger for semaglutide , the active ingredient in Ozempic, Wegovy and Rybelsus, than for the entire GLP-1 drug class. Patient safety message: Sudden or rapidly worsening vision loss is not a symptom to monitor at home. Anyone experiencing sudden vision loss while taking a GLP-1-based medi...
Read more

Healthy Lifestyle and Longevity (2026): The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Originally published: August 24, 2026 | Last updated: September 29, 2026 Quick Answer: A healthy lifestyle may add years to life, and potentially a decade or more in some populations, but no scientifically valid number applies to everyone. The biggest gains come from not smoking, regular physical activity, a high-quality diet, a healthy body weight, and controlled cardiovascular and metabolic risk factors . One influential U.S. analysis projected about 14 more years for women and 12 for men at age 50 for people with five low-risk habits versus none, but that is an observational estimate, not a guarantee. Supplements and anti-aging drugs are not proven to add a specific number of years. Preventing falls and injury also protects healthspan: balance and strength training is the best-supported strategy. In this guide What the Best Evidence Shows Other Studies Point the Same Way How Much Does Each Lifestyle...
Read more

Bryan Johnson's Supplements List: Insider's Guide (2026 Update)

Image
By Editorial Team , medically reviewed by Dr Frank Yap, MD | Last updated: August 2026 | Originally published: June 2024 Related: Bryan Johnson's Blueprint Longevity Mix Review Quick Answer Bryan Johnson's protocol has been substantially simplified since the 40+ item pill list he published in 2024. His January 2026 update replaces most of the granular, individually-dosed compounds (NAC, red yeast rice, DHEA, genistein, standalone taurine, and others) with combined formulations — Essential Capsules, Advanced Antioxidants, and a merged Ashwagandha & Rhodiola product — alongside NR or NMN, omega-3, and Proferrin. His daily creatine dose has increased to 7.5 g total. The bigger change is on the prescription side: he has added three cardiometabolic drugs not previously disclosed — the SGLT2 inhibitor Jardiance (empagliflozin) , the PCSK9 inhibitor Repatha (evolocumab) , and the ARB candesartan — and switched metformin from continuous daily dosing to a s...
Read more